Stockscreener 앱 받기
132.39
0.72%
-0.96
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR - simplywall.st
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data - simplywall.st
Neurocrine presents data showing INGREZZA achieved higher target occupancy - StreetInsider
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PR Newswire
Neurocrine Biosciences describes new GLP-1R/GIPR/GCGR agonists - BioWorld MedTech
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC - MarketBeat
With Neurocrine Biosciences, Inc. (NASDAQ:NBIX) It Looks Like You'll Get What You Pay For - 富途牛牛
Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Gap Down: Can Neurocrine Biosciences Inc be recession proofBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Price-Driven Insight from (NBIX) for Rule-Based Strategy - Stock Traders Daily
Investor Mood: What is the Moat Score of Harbor Etf Trust Smid Capital Value EtfWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Lobbying Update: $60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Peregrine Capital Management LLC Reduces Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure - Sahm
How Neurocrine Biosciences Inc. stock benefits from tech adoption2025 Short Interest & Weekly Breakout Stock Alerts - Улправда
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
Why Neurocrine Biosciences Inc. stock could be next big winnerInsider Buying & Safe Swing Trade Setups - ulpravda.ru
Entry Recap: How Neurocrine Biosciences Inc stock benefits from tech adoptionMarket Growth Summary & Long-Term Capital Growth Strategies - moha.gov.vn
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $169.00 at Truist Financial - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Equal Weight" Rating from Morgan Stanley - MarketBeat
NBIX Analyst Downgrade by Morgan Stanley with Raised Price Targe - GuruFocus
Neurocrine Bio. stock rating downgraded by Morgan Stanley on competition - Investing.com Canada
How Neurocrine Biosciences Inc. stock performs in weak economyStock Liquidity Analysis & Affordable Growth Trading - ulpravda.ru
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easingTechnical Analysis Insights & Crush the Market with Breakout Winners - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownHere's Why - MarketBeat
UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com - Investing.com Canada
Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
Allspring Global Investments Holdings LLC Has $52.39 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
13,364 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Pacer Advisors Inc. - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by Zacks Research to "Hold" - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Position Lessened by Simplify Asset Management Inc. - MarketBeat
Neurocrine Biosciences executive sells shares totaling $258,263 - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Burney Co. Has $4.05 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co
8.75%
1.45%
자본화:
|
볼륨(24시간):